focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hallo Sheppy, for anyone who isn’t aware of Sheppy, this resident board spammer has been posting exclusively on the Avacta board since the 18th May 2018. All posts negative despite trying to convince everyone he is invested in the share....Oh and he's also purporting to be very wealthy. Anyone want to see what the loud mouth trolls first post was on Avacta?
"All you so called investors are deluded with this share. It has done absolutely nothing but disappoint. You are all waiting for the deluded woooosh that is simply not going to happen. The only way this share goes is downwards. some people on here are talking about this being �4 a share �. more like 4p. There is no interest in it because its a no hoper...get real for god sake!"
The price on that date was 17.5p. If you'd bought at that price you could've sold at a 10x return.
They need Simon Bennett off the wage bill. The guy is stealing a living, a third of the year doing sweet fa. Given a free pass until H2 this year before Avacta announce a pipeline, so no deals before then either. Get the company sold and put me out of my misery.
No problem to me in the slightest
Sheppy you are getting one hell of a bashing on this BB today. 🤣🤣🤣
Jesus won’t save Avacta either
Jesus we are currently in commercial discussions and have strengthened our negotiating position, you either believe the deals will be forthcoming or you don’t, all this about oh you need xyz approvals first on previous drugs etc is hypothetical BS. The data on the platform is currently exceptional it sells itself, it won’t be BP dictating the term’s imo, Avacta will be in full control trying to maximise terms to benefit the company hence strengthening of Negotiation position. Why do you think they are so relaxed and excited about everything. Unfortunately MM games and a short position have caused mass panic here 19-20% Dilution caused an 80% drop didn’t think Avacta expected that tbh and totally not justified based on the fact nothing has materially changed since November (Al paid with his job), if Avacta were really concerned about share price they could release the early case studies to main stream media, the fact they haven’t bothered, suggest’s they know everything will take care of itself in time. These doom merchants crack me up 😆.
Rory, I agree that the finances are in a state. They need to get rid of the garbage in Dx, slim it to a profitable position so that it can contribute or be sold to give them the cash runway they need. A fire sale of Dx would also achieve that as 2026 could be the year that they get marketing approval for an indication for ava6k. They're not far off delivering commercially if you think in years rather than months and they're sat on enough to 'probably' see them to 2026. I also agree that the research pipeline that CC is excited about could be seen as a cash drain - unless their preliminary conversations lead to licencing opportunities from this PoC work. I'd prefer that they get ava6k over the line, start making cash and then start expanding their horizons. I'd be delighted for Simon to sign a deal and prove me very wrong.
You missed the second half of that point.
“It either needs to be approved, or developed to a point where it looks highly likely to be approved”
As for that list, the big pharma buyers have made a judgement about the likelihood of being approved. And at least a third of the companies had FDA-approved products or had completed registrational trials, I suspect all of the remainder had successfully completed phase 3 and phase 2 trials. I was invested in one of those companies which had multiple positive findings from phase 2 and 3 trials across multiple products.
So, you’ve just created a straw man.
And highlighted why it isn’t possible to have a rational, intelligent discussion on this board. There are ~5 people who comment on this board whose opinions I value. I’m hoping you will stop with your asinine comments and not put those people off from making a meaningful contribution.
I'm seeing Ads for a female mechanic working on a Mercedes-Benz brake system.
Makes me imagine Doggy muttering "I'm not bloody well taking my car for a service there".
Another CC (Cheryl Calverley) wrote and spoke plenty on the demise of Eve Sleep after the event. She could've had NDA agreements in place with Bensons Beds as she worked for them for a while as they bought Eve out of admin. Different situations of course but people would still like to know AS's view I'm sure.
Haha 🔥🔥🔥🔥🔥great post LLP.
Could be PJT, but he also might want to be supportive of CC and people read between the lines. Depends on the way he went I guess.
I hope that CC / the BOD every opportunity to maximise license deals and protect themselves a bit better than before the raise. They might have learned an important lesson there.
@Rory, Perhaps worth a bit of checking before statements like “Precision can’t be monetised as it isn’t approved for use.”
For example, ‘Top 20 biopharma deals of 2023’ …
https://www.nature.com/articles/d43747-023-00124-x
Platform/Discovery – 12
Preclinical/IND – 3
Phase 2 – 4
Phase 1 – 1
10 of the above Oncology.
pre|CISION™ platform and Affimer® will be ‘in play’.
GLA
D-Geeman, possible NDA and severance package should avoid that?
Will we still get Director / PDMR RNSs if AS sells or buys AVCT stock? I also wouldn't be surprised if there's a final Paul Hill interview with AS where AS puts his side of the story (all in due course rather than in hours or days).
You are Thorn alt account so many question marks, wow should have spotted it earlier. 🤣🤣👋👋
So, let’s say the results are stellar.
What results are you expecting? Ie. What do you expect the results to demonstrate?
What do you expect to happen on the back of those results? And to what timescales?
If you think like that the company is clearly not for you. I would sell up tbh. However i do love a good hypothetical scenario. Avacta clearly don’t think the platform can’t be monetised, they didn’t hire Simon to do FA and it’s a fact new and existing discussions are on going. I suppose we will need to see what happens over the next 12 months.
Rory, it entirely hinges on the quality of those results between now and the next funding round.
Heard enough from you Rory. Clueless so in the bin you go.
Rory
Dangerous to say anything rational that upsets the Pom Pom girls on here
By “Commercial powerhouse”, I presume you mean Simon Bennett?
You can throw around all the superlatives you’d like, but one man in a relatively unknown, UK-based, small-cap is not about to commercialise Precision single handedly.
Precision can’t be monetised as it isn’t approved for use. It either needs to be approved, or developed to a point where it looks highly likely to be approved, before it can be monetised. The company has a long way to go before it gets to this point; the 2-weekly dosing trial is still in its early stages - and the primary aim of this study is to establish a safe dose/RP2D.
By the time that milestone is reached, and findings shared, the company will be in a very poor financial position (once again) and potential suitors will exploit this; offering pennies on the pound for the IP or waiting for the company to slip into administration before picking it up for peanuts.
It’s a shame as the IP seems highly promising, but the company is plagued by gross incompetence on the commercial side.
🥲🥲🥲🥲🥲
Sheppy, I wasn't surprised at all to see you jumping on the back of Rory's lengthy, perfectly fair and 'considered' post, largely because - looking at your last 20 posts, you have not offered one single substantive or constructive thought. Virtually every one of your posts boils down to one or two lines (max - feel free to check) of nothing other than sniping - an easy option for anyone who can do little more than think on an empty head. I am not a censor here as I am not actually invested at present but I have followed Avacta for several years. Personally, the only justification that I can see for your existence here is to ensure that full advantage of the filter box is taken.
I think we can now see why Smith has gone - the awful move into Diagnostics.
These acquisitions cost nearly £32m in cash with more to pay on earn outs. Yet in the results just announced the segment has shown a loss of £13,448,000 after impairment (!!) of £5,225,000. Isn’t that just truly diabolical. After all the bullxxxt we were given they now want out and who is likely to buy at anywhere near the cost AV paid?
The current chairman and FD have to follow Smith out of the door since they can’t avoid responsibility for this shambles.